Temasek Holdings Private Ltd Buys New Holdings in Tempus AI, Inc. $TEM

Temasek Holdings Private Ltd bought a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the first quarter, Holdings Channel reports. The fund bought 7,462 shares of the company’s stock, valued at approximately $360,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. boosted its holdings in Tempus AI by 12.7% in the first quarter. First Horizon Advisors Inc. now owns 1,849 shares of the company’s stock valued at $89,000 after acquiring an additional 208 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Tempus AI by 13.2% during the fourth quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock worth $80,000 after purchasing an additional 278 shares in the last quarter. Bartlett & CO. Wealth Management LLC lifted its stake in shares of Tempus AI by 100.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company’s stock worth $39,000 after purchasing an additional 400 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Tempus AI by 10.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,594 shares of the company’s stock worth $268,000 after purchasing an additional 515 shares in the last quarter. Finally, Cherry Tree Wealth Management LLC acquired a new position in shares of Tempus AI during the first quarter worth about $31,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Trading Up 1.9%

NASDAQ:TEM opened at $79.62 on Friday. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54. Tempus AI, Inc. has a one year low of $31.36 and a one year high of $91.45. The business’s 50-day simple moving average is $65.39 and its 200 day simple moving average is $59.04. The stock has a market cap of $13.83 billion, a price-to-earnings ratio of -66.91 and a beta of 5.08.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The business had revenue of $314.64 million for the quarter, compared to analysts’ expectations of $296.84 million. During the same quarter in the previous year, the firm posted ($6.86) earnings per share. The company’s revenue was up 89.5% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Ryan Fukushima sold 17,460 shares of the business’s stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $1,303,389.00. Following the transaction, the chief operating officer owned 839,180 shares in the company, valued at approximately $62,644,787. The trade was a 2.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Theodore Leonsis sold 205,847 shares of the business’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $67.66, for a total value of $13,927,608.02. Following the completion of the transaction, the director owned 15,511 shares in the company, valued at approximately $1,049,474.26. This trade represents a 92.99% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,108,951 shares of company stock valued at $77,660,938. Insiders own 26.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Morgan Stanley boosted their price objective on Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 12th. HC Wainwright assumed coverage on Tempus AI in a research note on Tuesday, September 2nd. They set a “buy” rating and a $90.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $70.00 price objective on shares of Tempus AI in a research note on Friday, August 8th. Bank of America boosted their price objective on Tempus AI from $68.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 25th. Finally, Guggenheim boosted their price objective on Tempus AI from $65.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday, June 30th. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and a consensus price target of $69.50.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.